TABLE 1.
Clinical data of the whole cohort, patients with TFR loss, and patients with TFR still sustained. WBC: white blood cells; LY: lymphocyte count; TFR: treatment-free remission; MR: molecular response; TKI: tyrosine kinase inhibitor; yrs: years; and mos: months.
| Patient’s characteristics | Whole cohort (n = 109) | TFR loss (n = 38) | TFR sustained (n = 71) |
|---|---|---|---|
| Median age at diagnosis (range) | 53 years (19–76 years) | 51.5 years (27–76 years) | 54 years (19–76 years) |
| Sex | |||
| Male | 62 (57%) | 20 (53%) | 42 (59%) |
| Female | 47 (43%) | 18 (47%) | 29 (41%) |
| Median WBC at discontinuation (range) | 6000/mmc (3342–12680/mmc) | 6000/mmc (3767–12680/mmc) | 6040/mmc (3342–9,800/mmc) |
| Median LY (range) | 1680,5/mmc (1000–3465/mmc) | 1680,5/mmc (1000–3465/mmc) | 1700/mmc (1000–3400/mmc) |
| Sokal score | |||
| High | 16 (14.5%) | 4 (10.5%) | 12 (17%) |
| Intermediate | 38 (35%) | 12 (31.5%) | 26 (36.5%) |
| Low | 49 (45%) | 20 (53%) | 29 (41%) |
| Unknown | 6 (5.5%) | 2 (5%) | 4 (5.5%) |
| EUTOS score | |||
| High | 15 (14%) | 4 (10.5%) | 11 (15.5%) |
| Intermediate | 6 (5.5%) | 4 (10.5%) | 2 (3%) |
| Low | 82 (75%) | 28 (74%) | 54 (76%) |
| Unknown | 6 (5.5%) | 2 (5%) | 4 (5.5%) |
| BCR::ABL1 transcript | |||
| b2a2 | 27 (24.8%) | 11 (28.9%) | 16 (22.5%) |
| b3a2 | 54 (49.6%) | 18 (47.4%) | 36 (50.7%) |
| b2a2/b3a2 | 7 (6.4%) | 2 (5.3%) | 5 (7.1%) |
| b2a2/b3a3 | 1 (0.9%) | 1 (2.6%) | - |
| Absent | 1 (0.9%) | - | 1 (1.4%) |
| Unknown | 19 (17.4%) | 6 (15.8%) | 13 (18.3%) |
| Additional cytogenetic abnormalities | 3 (2.8%) | 1 (2.6%) | 2 (2.8%) |
| Median time to complete cytogenetic response (range) | 3 months (2–21 months) | 3 months (2–21 months) | 3 months (2–18 months) |
| Molecular Response after starting therapy 12 months | |||
| MR ≤ 3 | 56 (51.4%) | 15 (39.5%) | 41 (57.7%) |
| MR = 4 | 16 (14.7%) | 8 (21.1%) | 8 (11.3%) |
| MR = 4,5 | 14 (12.8%) | 8 (21.1%) | 6 (8.5%) |
| MR = 5 | 16 (14.7%) | 4 (10.5%) | 12 (16.9%) |
| Unknown | 7 (6.4%) | 3 (7.8%) | 4 (5.6%) |
| TKI therapy before discontinuation | |||
| Imatinib | 39 (35.8%) | 19 (50.0%) | 20 (28.2%) |
| Nilotinib | 49 (45%) | 11 (28.9%) | 38 (53.5%) |
| Dasatinib | 21 (19.2%) | 8 (21.1%) | 13 (18.3%) |
| Median TKI treatment duration (range) | 7 years (3–18 years) | 7 years (7–18 years) | 7.5 years (3–17 years) |
| Median TKI treatment duration according to TKI | |||
| Imatinib | 8 years (4–18 years) | 8 years (4–18 years) | 8 years (4–16 years) |
| Nilotinib | 7 years (3–17 years) | 7 years (3–12 years) | 7 years (3–17 years) |
| Dasatinib | 8 years (3–15 years) | 8 years (4–14 years) | 8 years (3–15 years) |
| Median observation time (range) | 33 months (2–63 months) | 35 months (4–60 months) | 32 months (2–63 months) |